Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Here’s Why

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $31.74, but opened at $29.15. Hemab Therapeutics shares last traded at $28.24, with a volume of 4,535 shares traded.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price objective on the stock. Finally, Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Hemab Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.

Hemab Therapeutics Price Performance

Hemab Therapeutics (NASDAQ:COAG) last posted its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the company’s stock in a transaction on Monday, May 4th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This represents a 77.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have bought 2,970,541 shares of company stock worth $55,459,603.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.